TNGX
Tango Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 595.91K | $14.87M | n/a | n/a |
| Q2 2026 | 97 | +23 | 90.52M | $2.83B | +25 | −2 |
| Q1 2026 | 77 | 0 | 72.21M | $1.51B | +9 | −9 |
| Q4 2025 | 76 | 0 | 64.83M | $574.42M | +1 | −1 |
| Q3 2025 | 19 | +2 | 27.21M | $228.58M | +3 | −1 |
| Q2 2025 | 14 | 0 | 22.55M | $115.47M | +1 | −1 |
| Q1 2025 | 11 | +1 | 6.63M | $9.09M | +2 | −1 |
| Q4 2024 | 10 | 0 | 4.99M | $15.42M | +3 | −3 |
| Q3 2024 | 9 | -1 | 6.83M | $52.57M | +1 | −2 |
| Q2 2024 | 10 | n/a | 5.64M | $48.44M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 595.91K | -13.7% | $14.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 180.17M shares, $3.72B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 600 sh · $15,192
Officer · 26.40K sh · $645,604
Officer · 2.40K sh · $60,412
Officer · 700 sh · $15,962
Officer · 5.10K sh · $122,238
Officer · 27.00K sh · $603,909
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology